Cat's claw trials for rheumatoid arthritis
In this trial, 40 participants with rheumatoid arthritis took part in the following phases:
- Phase A – participants were randomised to receive either cat’s claw tablets (60 mg of Uncariae tomentosae) or placebo tablets once a day for 24 weeks
- Phase B – both treatment groups took cat’s claw for an additional 28 weeks.
All participants were asked to continue their usual treatment of sulfasalazine or hydroxychloroquine during both phases of the trial.
- 53% of participants given cat’s claw in phase A reported a significant reduction in the number of painful joints compared to only 24% of participants who started on placebo tablets.
- Participants in both groups didn’t differ with respect to morning stiffness and number of tender or swollen joints during this period.
- Significant beneficial effects on all clinical aspects were observed in participants who were given cat’s claw for both phases when compared to the placebo group.
- Minor side-effects (like stomach upsets) were reported in participants who received cat’s claw.